News
GSK’s Omjjara EU-cleared for splenomegaly in myelofibrosis
GSK’s $1.9 billion takeover of Sierra Oncology has delivered the first new product, with the EU approval of Omjjara for the treatment of enlarged spleen (splenomegaly) or
